Blog

Novo’s Wegovy and J&J’s Tremfya Lead Pharmaceutical Ad Spending Surge During March Madness

Emilia Wright | April 8, 2025

Responsive image

Novo’s Wegovy, J&J’s Tremfya Boost TV Ad Spending During March Madness

In a notable shift in advertising dynamics within the pharmaceutical sector, Novo Nordisk’s publicity surge for its obesity treatment, Wegovy, alongside Johnson & Johnson’s enhanced spending for Tremfya, is indicative of a strategic pivot towards engaging audiences during the historically significant March Madness basketball tournament. Recent data reveals that the top ten pharmaceutical spenders collectively allocated an impressive $248 million on TV drug advertising in March, representing a harmonious balance between January’s soaring $302.5 million and February’s sharp drop to $204.5 million.

Change in Spending Trends

The current trends reveal a significant transformation in the advertising landscape for the pharmaceutical industry. Last year, AbbVie’s Skyrizi and Rinvoq dominated the TV ad spending rankings, securing the top positions consistently. However, the first quarter of 2025 has painted a different picture. The two AbbVie products have only managed to achieve top-two monthly rankings on one occasion thus far, representing a stark contrast to their stronghold in early 2024.

In both January and March of 2025, Skyrizi and Rinvoq have slipped to third and fourth positions respectively, overtaken by Novartis’ Pluvicto and Johnson & Johnson’s Tremfya in January and more recently by Novo Nordisk’s Wegovy and Tremfya again in March.

March’s Top Ad Spenders

Leading the charge in ad spending for March were:

1. Wegovy by Novo Nordisk

  • Estimated National TV Ad Spend: $40.4 million (up from $25.8 million in February)
  • Number of Spots: 1
  • Biggest-ticket Ad: “Discover the Power: $0” (Estimated spend: $40.4 million)

2. Tremfya by Johnson & Johnson

  • Estimated National TV Ad Spend: $32.6 million (up from $20.1 million in February)
  • Number of Spots: 4 (one ulcerative colitis, three psoriasis)
  • Biggest-ticket Ad: “Break Away” (Estimated spend: $23.3 million)

3. Rinvoq by AbbVie

  • Estimated National TV Ad Spend: $29.2 million (down from $34.8 million in February)
  • Number of Spots: 5 (two eczema, two UC/Crohn’s, one arthritis)
  • Biggest-ticket Ad: “Just Okay: Jet Ski” (Estimated spend: $11.7 million)

4. Skyrizi by AbbVie

  • Estimated National TV Ad Spend: $27.9 million (up from $27 million in February)
  • Number of Spots: 6 (four psoriasis, one Crohn’s/UC, one psoriatic arthritis)
  • Biggest-ticket Ad: “In the Picture” (Estimated spend: $15.1 million)

5. Rexulti by Lundbeck and Otsuka

  • Estimated National TV Ad Spend: $26.2 million (up from $19.3 million in February)
  • Number of Spots: 2 (one depression, one Alzheimer’s)
  • Biggest-ticket Ad: “Still Masking: Garage and Office” (Estimated spend: $18.1 million)

6. Ozempic by Novo Nordisk

  • Estimated National TV Ad Spend: $21.7 million (up from $10.6 million in February)
  • Number of Spots: 3
  • Biggest-ticket Ad: “Testimonials: Michael and Tanya” (Estimated spend: $16.1 million)

7. Dupixent by Sanofi and Regeneron

  • Estimated National TV Ad Spend: $20.9 million (down from $22.4 million in February)
  • Number of Spots: 6 (two asthma, four eczema)
  • Biggest-ticket Ad: “Kenny” (Estimated spend: $7.9 million)

8. Zepbound by Eli Lilly

  • Estimated National TV Ad Spend: $19 million (up from $8.4 million in February)
  • Number of Spots: 4
  • Biggest-ticket Ad: “Change: What’s Possible” (Estimated spend: $13.8 million)

9. Jardiance by Eli Lilly and Boehringer Ingelheim

  • Estimated National TV Ad Spend: $15.8 million (up from $13.9 million in February)
  • Number of Spots: 3 (one CKD, two diabetes)
  • Biggest-ticket Ad: “Musical: Store” (Estimated spend: $11.2 million)

10. Vraylar by AbbVie

  • Estimated National TV Ad Spend: $14.3 million (up from $8.9 million in February)
  • Number of Spots: 3 (one depression, two bipolar)
  • Biggest-ticket Ad: “Stuck in My Head: Basketball” (Estimated spend: $11.2 million)

Conclusion

The pharmaceutical advertising landscape is undergoing a clear transformation as companies like Novo Nordisk and Johnson & Johnson capitalize on significant cultural events to enhance exposure and engagement. With the advent of March Madness providing a compelling backdrop, it will be interesting to observe if these investment patterns will persist and influence overall sales trends in the health industry moving forward.